AGILERA PHARMA AS
Operating
Drive forskning, utvikling og produksjon av nye løsninger for medisin
ved bruk av radioaktive kilder, samt andre aktiviteter som står i
forbindelse hermed, herunder samarbeid med, deltakelse og eierskap i
andre selskaper.
Produksjon av farmasøytiske preparater.
Keywords
productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings
Organization
- CEO
- EF
Erik Flatmark1962
- Chairman of the board
- NM
- Years since formation
- 5 years
- since Dec 1, 2021
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 136
Ownership
- Number of shares and share classes
- 30,000
- 1 share class
- Total number of shareholders
- 1
- company
- Belongs to group of
Financials
- Total operating income 2025
- 352,523,392
- NOK
- Annual total result 2025
- -69,620,391
- NOK
- Total equity 2025
- 18,463,486
- NOK
Last update: Jul 15, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
EF 1962 | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
NM | Chairman | - |
TM | Board Member | - |
ES | Board Member | - |
AE | Board Member | - |
IL | Alternate Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - |
Last update: Jun 12, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 30,000 | 100 % |
Last update: Jun 2, 2025
Group structure
- Total operating income 2025: NOK 1,097,183,000Operating profit 2025: NOK 10,856,000Employees: 583
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2021 |
|---|---|---|---|---|
Total operating income | 352,523,392 | 357,641,299 | 290,815,663 | 0 |
Annual Total Result | -69,620,391 | -34,750,295 | -8,318,746 | -1,200 |
Total assets | 185,094,511 | 149,224,699 | 157,781,387 | 23,230 |
Total liabilities | 166,631,025 | 134,202,886 | 108,009,279 | 0 |
Total equity | 18,463,486 | 15,021,814 | 49,772,108 | 23,230 |
P&L
| Year | 2025 | 2024 | 2023 | 2021 |
|---|---|---|---|---|
Total operating income | 352,523,392 | 357,641,299 | 290,815,663 | 0 |
Total operating costs | 416,495,934 | 386,633,157 | 300,877,604 | 1,200 |
Operating result | -63,972,542 | -28,991,858 | -10,061,942 | -1,200 |
Financial income/costs | -5,647,849 | -3,460,433 | -554,808 | 0 |
Profit before tax | -69,620,391 | -32,452,291 | -10,616,750 | -1,200 |
Total tax & extraordinary income/cost | 0 | 2,298,004 | -2,298,004 | 0 |
Annual Total Result | -69,620,391 | -34,750,295 | -8,318,746 | -1,200 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2021 |
|---|---|---|---|---|
Total fixed assets | 54,094,992 | 48,759,388 | 52,008,092 | 0 |
Total current assets | 130,999,519 | 100,465,311 | 105,773,294 | 23,230 |
Total assets | 185,094,511 | 149,224,699 | 157,781,387 | 23,230 |
Short term debt | 79,076,263 | 89,202,886 | 108,009,279 | 0 |
Long term debt | 87,554,762 | 45,000,000 | 0 | 0 |
Total liabilities | 166,631,025 | 134,202,886 | 108,009,279 | 0 |
Contributed capital | 88,083,877 | 15,021,814 | 49,772,108 | 24,430 |
Retained earnings | -69,620,391 | 0 | 0 | -1,200 |
Total equity | 18,463,486 | 15,021,814 | 49,772,108 | 23,230 |
Total equity and liabilities | 185,094,511 | 149,224,699 | 157,781,387 | 23,230 |
Classification
21st company classification
BETA
Industrial large enterprise
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations